Roche Holding AG Share Price Deutsche Boerse AG

Equities

RHO

CH0012032113

Pharmaceuticals

Delayed Deutsche Boerse AG 09:11:39 28/06/2019 pm IST 5-day change 1st Jan Change
247.6 EUR +0.81% Intraday chart for Roche Holding AG -.--% -.--%

Financials

Sales 2024 * 60.06B 66.4B 61.61B 5,532B Sales 2025 * 63.84B 70.57B 65.48B 5,880B Capitalization 173B 191B 177B 15,920B
Net income 2024 * 13.32B 14.73B 13.66B 1,227B Net income 2025 * 14.75B 16.31B 15.13B 1,359B EV / Sales 2024 * 3.11 x
Net Debt 2024 * 14.24B 15.74B 14.61B 1,312B Net Debt 2025 * 8.16B 9.03B 8.37B 752B EV / Sales 2025 * 2.84 x
P/E ratio 2024 *
12.6 x
P/E ratio 2025 *
11.4 x
Employees 1,03,605
Yield 2024 *
4.54%
Yield 2025 *
4.7%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart
5 years
225.00
Extreme 225
252.60
10 years
181.60
Extreme 181.6
270.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 01/03/01
Chairman 57 01/08/01
Director of Finance/CFO 57 01/11/01
Members of the board TitleAgeSince
Director/Board Member 72 03/15/03
Director/Board Member 59 -
Director/Board Member 66 01/96/01
More insiders
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
214.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+30.49%
Consensus